Rami Hannoush
Inversor de Capital Privado en Versant Venture Management LLC .
Perfil
Rami Hannoush is the founder of EpiBiologics, Inc. He is currently a Venture Partner at Versant Venture Management LLC.
Previously, he worked as a General Partner at Mubadala Capital and as a Board Member at Juvena Therapeutics, Inc. Hannoush holds a doctorate degree from McGill University and a graduate degree from Harvard Medical School.
Cargos activos de Rami Hannoush
Empresas | Cargo | Inicio |
---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Inversor de Capital Privado | 01/02/2023 |
Antiguos cargos conocidos de Rami Hannoush.
Empresas | Cargo | Fin |
---|---|---|
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Director Ejecutivo | 20/07/2023 |
Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. BiotechnologyHealth Technology Juvena Therapeutics, Inc. develops protein-based therapeutics that promotes tissue regeneration in the elderly. The company was founded by Hanadie Yousef and Jeremy O'connell in 2017 and is headquartered in Palo Alto, CA. | Director/Miembro de la Junta | 01/03/2023 |
Mubadala Capital
Mubadala Capital Investment ManagersFinance Mubadala Capital (Mubadala Capital) is a private equity subsidiary of Mubadala Investment Co. PJSC founded in 2011. The firm is headquartered in Abu Dhabi, United Arab Emirates with offices in London, New York, Rio De Janeiro, and San Francisco. | Inversor de Capital Privado | 01/02/2023 |
Formación de Rami Hannoush.
McGill University | Doctorate Degree |
Harvard Medical School | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Mubadala Capital
Mubadala Capital Investment ManagersFinance Mubadala Capital (Mubadala Capital) is a private equity subsidiary of Mubadala Investment Co. PJSC founded in 2011. The firm is headquartered in Abu Dhabi, United Arab Emirates with offices in London, New York, Rio De Janeiro, and San Francisco. | Finance |
Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. BiotechnologyHealth Technology Juvena Therapeutics, Inc. develops protein-based therapeutics that promotes tissue regeneration in the elderly. The company was founded by Hanadie Yousef and Jeremy O'connell in 2017 and is headquartered in Palo Alto, CA. | Health Technology |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Commercial Services |
- Bolsa de valores
- Insiders
- Rami Hannoush